Download Free Sample Report

Biosimilar of Remicade Market, Global Outlook and Forecast 2023-2035

Biosimilar of Remicade Market, Global Outlook and Forecast 2023-2035

  • Published on : 18 August 2023
  • Pages :104
  • Report Code:SMR-7780359

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product.
This report aims to provide a comprehensive presentation of the global market for Biosimilar of Remicade, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar of Remicade. This report contains market size and forecasts of Biosimilar of Remicade in global, including the following market information:
Global Biosimilar of Remicade Market Revenue, 2018-2023, 20242035, ($ millions)
Global top five companies in 2022 (%)
The global Biosimilar of Remicade market was valued at US$ 307660 million in 2022 and is projected to reach US$ 490500 million by 2029, at a CAGR of 6.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Monoclonal Antibodies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Biosimilar of Remicade include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Biosimilar of Remicade companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilar of Remicade Market, by Type, 2018-2023, 20242035 ($ millions)
Global Biosimilar of Remicade Market Segment Percentages, by Type, 2022 (%)
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Global Biosimilar of Remicade Market, by Application, 2018-2023, 20242035 ($ millions)
Global Biosimilar of Remicade Market Segment Percentages, by Application, 2022 (%)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Biosimilar of Remicade Market, By Region and Country, 2018-2023, 20242035 ($ Millions)
Global Biosimilar of Remicade Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilar of Remicade revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Biosimilar of Remicade revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biosimilar of Remicade, market overview.
Chapter 2: Global Biosimilar of Remicade market size in revenue.
Chapter 3: Detailed analysis of Biosimilar of Remicade company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilar of Remicade in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.